Other · developed by OPKO Health
OPK-88003 is an agent given by subcutaneous injection. It is studied in type 2 diabetes mellitus.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT03406377 | Phase 2 | Type 2 Diabetes Mellitus | Completed | OPK |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Type 2 Diabetes Mellitus
Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.
See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
OPK catalysts and pipeline →